Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients

References

• TonelliMPannuNMannsBOral phosphate binders in patients with kidney failureN Engl J Med2010362141312132420375408
   PubMed Web of Science ®Google Scholar
• FriedmanEAConsequences and management of hyperphosphatemia in patients with renal insufficiencyKidney Int Suppl200595S1S715882307
   PubMedGoogle Scholar
• LopesAATongLThummaJPhosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional statusAm J Kidney Dis20126019010122385781
   PubMed Web of Science ®Google Scholar
• KestenbaumBSampsonJNRudserKDSerum phosphate levels and mortality risk among people with chronic kidney diseaseJ Am Soc Nephrol200516252052815615819
   PubMed Web of Science ®Google Scholar
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)Kidney Int Suppl2009113S1S130
   Google Scholar
• HruskaKAMathewSLundRQiuPPrattRHyperphosphatemia of chronic kidney diseaseKidney Int200874214815718449174
   PubMed Web of Science ®Google Scholar
• LiuLWangYChenHZhuXZhouLYangYThe effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trialsRen Fail201419
   Web of Science ®Google Scholar
• GoodmanWGVascular calcification in chronic renal failureLancet200135892881115111611597661
   PubMed Web of Science ®Google Scholar
• MallucheHHAluminium and bone disease in chronic renal failureNephrol Dial Transplant200217Suppl 2212411904354
   PubMed Web of Science ®Google Scholar
• ChertowGMBurkeSKRaggiPTreat to Goal Working GroupSevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney Int200262124525212081584
   PubMed Web of Science ®Google Scholar
• OkaYMiyazakiMMatsudaHSevelamer hydrochloride dose-dependent increase in prevalence of severe acidosis in hemodialysis patients: analysis of nationwide statistical survey in JapanTher Apher Dial2014181374324499082
   PubMed Web of Science ®Google Scholar
• TakahashiYTanakaANakamuraTNicotinamide suppresses hyperphosphatemia in hemodialysis patientsKidney Int20046531099110414871431
   PubMed Web of Science ®Google Scholar
• SampathkumarKSelvamMSoorajYSGowthamanSAjeshkumarRNExtended release nicotinic acid – a novel oral agent for phosphate controlInt Urol Nephrol200638117117416502077
   PubMed Web of Science ®Google Scholar
• MullerDMehlingHOttoBNiacin lowers serum phosphate and increases HDL cholesterol in dialysis patientsClin J Am Soc Nephrol2007261249125417913971
   PubMed Web of Science ®Google Scholar
• Restrepo ValenciaCACruzJSafety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemiaNefrologia20082816166 Spanish18336133
   PubMed Web of Science ®Google Scholar
• KataiKTanakaHTatsumiSNicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestineNephrol Dial Transplant19991451195120110344361
   PubMed Web of Science ®Google Scholar
• EtoNMiyataYOhnoHYamashitaTNicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failureNephrol Dial Transplant20052071378138415870221
   PubMed Web of Science ®Google Scholar
• AramwitPSrisawadwongRSupasyndhOEffectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patientsJ Nephrol201225335436221748722
   PubMed Web of Science ®Google Scholar
• TothPPHigh-density lipoprotein and cardiovascular riskCirculation2004109151809181215096460
   PubMed Web of Science ®Google Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• BarterPGottoAMLaRosaJCHDL cholesterol, very low levels of LDL cholesterol, and cardiovascular eventsN Engl J Med2007357131301131017898099
   PubMed Web of Science ®Google Scholar
• PieperJAOverview of niacin formulations: differences in pharmacokinetics, efficacy, and safetyAm J Health Syst Pharm20036013 Suppl 2S9S14 quiz S2512901025
   PubMed Web of Science ®Google Scholar
• Group HTCLandrayMJHaynesREffects of extended-release niacin with laropiprant in high-risk patientsN Engl J Med2014371320321225014686
   PubMed Web of Science ®Google Scholar
• ChengSCYoungDOHuangYDelmezJACoyneDWA randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patientsClin J Am Soc Nephrol2008341131113818385391
   PubMed Web of Science ®Google Scholar
• YoungDOChengSCDelmezJACoyneDWThe effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patientsPerit Dial Int200929556256719776051
   PubMed Web of Science ®Google Scholar
• ShahbazianHZafar MohtashamiAGhorbaniAOral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trialNefrologia2011311586521270914
   PubMed Web of Science ®Google Scholar
• Edalat-NejadMZameniFTalaieiAThe effect of niacin on serum phosphorus levels in dialysis patientsIndian J Nephrol201222317417823087550
   PubMedGoogle Scholar
• AhmadiFShamekhiFLessan-PezeshkiMKhatamiMRComparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patientsSaudi J Kidney Dis Transpl201223593493822982903
   PubMedGoogle Scholar
• CannerPLBergeKGWengerNKFifteen year mortality in Coronary Drug Project patients: long-term benefit with niacinJ Am Coll Cardiol198686124512553782631
   PubMed Web of Science ®Google Scholar
• Clofibrate and niacin in coronary heart diseaseJAMA197523143603811088963
   PubMed Web of Science ®Google Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341641041810438259
   PubMed Web of Science ®Google Scholar
• KamannaVSGanjiSHKashyapMLThe mechanism and mitigation of niacin-induced flushingInt J Clin Pract20096391369137719691622
   PubMed Web of Science ®Google Scholar
• DaltonTABerryRSHepatotoxicity associated with sustained-release niacinAm J Med19929311021041626557
   PubMed Web of Science ®Google Scholar
• RennickAKalakecheRSeelLSheplerBNicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patientsPharmacotherapy201333668369023526664
   PubMed Web of Science ®Google Scholar